---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-027444"
form_type: "8-K"
ticker: "ALMS"
cik: "0001847367"
company_name: "ALUMIS INC."
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T05:59:54.122264+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alumis licenses ESK-001 to Kaken for Japan; $40M upfront/near-term plus $140M milestones

## Summary
- Alumis receives $20M upfront and $20M co-development payments from Kaken in 2025-2026.
- Kaken gets exclusive rights to develop/commercialize ESK-001 for dermatology in Japan, with options for rheumatology and GI.
- Alumis retains rights outside Japan; Kaken contributes to global development costs.
- Cash runway extended through Phase 3 ONWARD psoriasis topline data readout.
- Tiered royalties on Japan net sales: low double-digits to twenties percent.

## SEC filing metadata
- accession: 0001104659-25-027444
- form_type: 8-K
- ticker: ALMS
- cik: 0001847367
- company_name: ALUMIS INC.
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847367/000110465925027444/0001104659-25-027444-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847367/000110465925027444/tm2510181d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-027444
- JSON: https://secwatch.observer/filing/0001104659-25-027444.json
- Plain text: https://secwatch.observer/filing/0001104659-25-027444.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.